All In Biotech

Drug Trial Radar · NCT05829655

Measuring Acute Drug Demand in Humans

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Aug 8, 2023

Primary completion

Jan 1, 2028

Study completion Jan 1, 2028

Sponsor

Lead sponsor
University of Maryland, BaltimoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Apr 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

Conditions

  • Opioid Use Disorder
  • Opioid Dependence

Interventions

  • Drug A (Blinded Drug)Drug

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • Drug B (Blinded Drug)Drug

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • Drug C (Blinded Drug)Drug

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • Drug D (Blinded Drug)Drug

    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

  • Suvorexant (20mg/day)Drug

    Double blind administration of suvorexant once per day during residential stay until discharge.

  • PlaceboDrug

    Double blind administration of placebo once per day during residential stay until discharge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demand IntensityTime frame: Upon completion of experimental session (~8 hours post drug administration)
  2. Demand ElasticityTime frame: Upon completion of experimental session (~8 hours post drug administration)
  3. Cross-Price ElasticityTime frame: After Experimental Session 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Clinical Research Center

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.